FORTE
What it found
The trial ended early for another reason (see below).
What was tested
Treatment tested
- Glatiramer acetate
Unknown
Compared with
- Glatiramer acetate
Unknown
What it measured
Main measures
Total number of confirmed relapses.
Relapses
Who could take part
Relapsing MS
Inclusion: 1. Subjects must have a confirmed and documented MS diganosis as defined by the Revised McDonald criteria [Ann Neurol 2005: 58:840-846]. Exclusion: 1. Any treatment with corticosteroids (IV, IM and/or PO) within 30 days prior to screening.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To compare the efficacy of daily subcutaneous injections of 40 mg glatiramer acetate (GA) to that of 20 mg GA (Copaxone) in RR MS patients as determined by the confirmed relapse rates.
Loading reviews and guidelines…
Related trials
- TWINS
Phase 3 · Not yet recruiting
Still running
- AIOLOS
Recruiting
Still running
- Full Responders
Phase 4 · Stopped early
Stopped early
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- A Open-label Study to Assess Response to COVID-19 Vaccine…
Phase 4 · Stopped early
Stopped: safety
- A Study to Asses Efficacy, Safety and Tolerability of Mon…
Phase 3 · Completed
Met its main goal
History
Started
May 2006
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error